A Phase Ⅰ Study Evaluating Safety and Efficacy of C-CAR088 Treatment in Subjects With Relapsed or Refractory Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Dec 2021 Updated results of the study (NCT03751293, NCT03815383, NCT04322292, NCT04295018) with more patients and longer follow up time presented at the 63rd American Society of Hematology Annual Meeting and Exposition
08 Dec 2020 Pooled results from NCT04322292,NCT03815383,NCT03751293 and NCT04295018 presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology
09 Nov 2020 According to a Cellular Biomedicine Group media release, results from this study will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com